Literature DB >> 8032344

Purine metabolism in the heart. Strategies for protection against myocardial ischaemia.

K Ver Donck1.   

Abstract

Adenosine has recently received much attention for the protection it provides against the deleterious effects of ischaemia reperfusion. Whenever the demand for oxygen exceeds its supply, adenosine triphosphate in myocytes is rapidly dephosphorylated to adenosine. Adenosine may then protect the myocardium against ischaemia-reperfusion damage. However, the accumulation of adenosine is limited by its rapid uptake and catabolism in the endothelium and in red blood cells. The strict compartmentalization of the enzyme pathways involved in the metabolism of adenosine, e.g. adenosine production by myocytes, its pharmacological action in the interstitium, its catabolism in the endothelium and in red blood cells, and its carrier-mediated transport across membranes, provides a unique target for pharmacological interventions. Blockade of adenosine uptake may indeed result in prolonged adenosine accumulation specifically in those regions of the heart where it is produced. In recent years considerable evidence has been gathered on the adenosine-mediated cardioprotective actions of nucleoside transport inhibitors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032344     DOI: 10.1007/bf01880658

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  70 in total

Review 1.  Free radical and granulocyte-mediated injury during myocardial ischemia and reperfusion.

Authors:  R L Engler
Journal:  Am J Cardiol       Date:  1989-03-07       Impact factor: 2.778

2.  The antiarrhythmic effects of the nucleoside transporter inhibitor, R75231, in anaesthetized pigs.

Authors:  C L Wainwright; J R Parratt; H Van Belle
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

3.  The effect of adenosine on myocardial metabolism and oxygen consumption in the isolated dog heart preparation.

Authors:  G J Jesmok; G J Gross; H F Hardman
Journal:  J Mol Cell Cardiol       Date:  1978-03       Impact factor: 5.000

4.  Polymorphonuclear leukocyte activity and ventricular arrhythmia in acute myocardial infarction.

Authors:  T Kuzuya; S Hoshida; K Suzuki; T Sasaki; A Kitabatake; T Kamada; T Minamino; M Tada
Journal:  Am J Cardiol       Date:  1988-11-01       Impact factor: 2.778

5.  Mioflazine, a potentially protective drug against ischaemic damage: a study in dogs.

Authors:  A J Wood; K Isted; J Hynd; M J Main; M I Noble; J Parker; A J Drake-Holland
Journal:  Eur Heart J       Date:  1985-08       Impact factor: 29.983

Review 6.  Protective effects of adenosine in myocardial ischemia.

Authors:  S W Ely; R M Berne
Journal:  Circulation       Date:  1992-03       Impact factor: 29.690

7.  Role of nucleoside transport inhibition and endogenous adenosine in prevention of catecholamine induced death in rabbits.

Authors:  H Van Belle; K Ver Donck; W Verheyen
Journal:  Cardiovasc Res       Date:  1993-01       Impact factor: 10.787

8.  Cardiac adenosine production is linked to myocardial pO2.

Authors:  A Deussen; J Schrader
Journal:  J Mol Cell Cardiol       Date:  1991-04       Impact factor: 5.000

9.  Significance of plasma adenosine in the antiplatelet activity of forskolin: potentiation by dipyridamole and dilazep.

Authors:  K C Agarwal; B A Zielinski; R S Maitra
Journal:  Thromb Haemost       Date:  1989-02-28       Impact factor: 5.249

10.  Formation and release of purine catabolites during hypoperfusion, anoxia, and ischemia.

Authors:  H Van Belle; F Goossens; J Wynants
Journal:  Am J Physiol       Date:  1987-05
View more
  2 in total

1.  A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine.

Authors:  E Snoeck; P Jacqmin; A Van Peer; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1999-06

2.  Multiomics approach reveals metabolic changes in the heart at birth.

Authors:  Jacquelyn M Walejko; Jeremy P Koelmel; Timothy J Garrett; Arthur S Edison; Maureen Keller-Wood
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-10-09       Impact factor: 4.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.